Transcode Therapeutics, Inc.
RNAZ- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829635
No open-market purchases or sales by Transcode Therapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $208.1K in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Transcode Therapeutics, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 7 | 15 | +8 |
| Shares | 417.1K | 262.1K | −154.9K (−37.1%) |
| Value | $284.1K | $263.0K | −$21.1K (−7.4%) |
New holders (10)
Institutions that held Transcode Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 74,924 | $75.3K | 0.00% |
| Geode Capital Management, LLC | 38,398 | $38.6K | 0.00% |
| Citadel Advisors LLC | 25,512 | $25.6K | 0.00% |
| Susquehanna International Group, LLP | 24,253 | $24.4K | 0.00% |
| Sheets Smith Wealth Management | 20,138 | $20.2K | 0.00% |
| Private Capital Management LLC | 17,518 | $17.6K | 0.00% |
| Captrust Financial Advisors | 11,250 | $11.3K | 0.00% |
| Morgan Stanley | 10,000 | $10.1K | 0.00% |
| Financial Network Wealth Advisors LLC | 1,000 | $1.00K | 0.00% |
| Bank of America Corp | 55 | $55 | 0.00% |
Sold out (2)
Institutions that held Transcode Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Sabby Management, LLC | 334,823 | $228.7K |
| Wells Fargo & Company | 5 | $3 |